CGRI Canada CDKL5 Genetic Research Initiative

Research and hope for families living with CDKL5 deficiency disorder

The CDKL5 Genetic Research Initiative Canada (CGRI Canada) is a Canadian nonprofit working to advance genetic research for CDKL5 deficiency disorder in Canada, and to advance health and education for people affected by the disorder and for the families and caregivers who stand with them.

Illustration of a parent holding a young child's hand as they look up at a glowing DNA double helix
Est. 2026
Founded in Canada in 2026
Nonprofit
A Canadian nonprofit organization
Ontario, Canada
Serving CDKL5 families and researchers across Canada

Our mission

CGRI Canada exists to advance genetic research for CDKL5 deficiency disorder in Canada, and to support better health, better knowledge, and better lives for people affected by the disorder.

CDKL5 deficiency disorder is a rare genetic condition. For the children and adults who live with it, and for their families, every advance in research and every piece of reliable, accessible information matters.

CGRI Canada was founded to advance genetic research for CDKL5 deficiency disorder in Canada, and to advance health and education for persons affected by the disorder. We connect Canadian families, clinicians, and researchers, and we support the research momentum that leads to better care and, one day, better treatments.

  • Advance research

    Support and promote research into CDKL5 deficiency disorder, its causes, and future treatments.

  • Educate and inform

    Share clear, trustworthy information about CDKL5 deficiency disorder with families, caregivers, and the public.

  • Connect the community

    Bring together Canadian families, clinicians, and researchers so no one faces this disorder alone.

About CDKL5 deficiency disorder

CDKL5 deficiency disorder (CDD) is a rare neurodevelopmental disorder caused by changes in the CDKL5 gene, which provides instructions for a protein essential to normal brain development.

The disorder is typically marked by seizures that begin in the first months of life and by significant developmental challenges. Many children with CDD have limited or no speech and need lifelong support with everyday activities.

There is currently no cure. Care focuses on managing symptoms, but research is moving quickly, and genetic therapies are an active area of study worldwide.

Why research matters

Because CDD is rare, progress depends on families, clinicians, and researchers working together, sharing knowledge, taking part in studies, and keeping the condition visible. CGRI Canada helps Canadian families be part of that effort and helps Canadian research reach the families it serves.

Newly diagnosed?

A CDKL5 diagnosis can feel overwhelming. If your family has recently received one, you are welcome to reach out. We can help you find information and connect with the wider CDKL5 community.

Gene therapy research

One of the most hopeful areas of CDKL5 research is gene therapy: an approach that aims to treat the cause of the disorder, not only its symptoms.

CDKL5 deficiency disorder is rare, affecting about 1 in 40,000 children. It happens when the CDKL5 gene is missing or not working properly, and it can cause developmental delays and seizures, often starting early in life.

Researchers are working on an AAV9 gene therapy. It uses AAV9 as a delivery system to bring a healthy copy of the CDKL5 gene to brain cells, targeting the root cause of the disorder rather than just managing its symptoms.

The therapy is designed as a one-time dose with durable benefit, and it builds on proven AAV9 platforms already used in conditions such as SMA and MLD.

Early results, real hope

In early studies in mice, this approach has shown better movement, thinking, and brain health. The research is now progressing toward human trials, bringing new hope to families affected by CDKL5 deficiency disorder.

Learn more

This is general background on research in the wider CDKL5 field. To learn more, visit cdkl5genetherapy.com.

Contact us

Whether you are a family member, a clinician, a researcher, or simply want to learn more. We would love to hear from you.